Cargando…

Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression

Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Oehl, Kathrin, Kresoja-Rakic, Jelena, Opitz, Isabelle, Vrugt, Bart, Weder, Walter, Stahel, Rolf, Wild, Peter, Felley-Bosco, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829086/
https://www.ncbi.nlm.nih.gov/pubmed/29527515
http://dx.doi.org/10.3389/fonc.2018.00040
_version_ 1783302732779618304
author Oehl, Kathrin
Kresoja-Rakic, Jelena
Opitz, Isabelle
Vrugt, Bart
Weder, Walter
Stahel, Rolf
Wild, Peter
Felley-Bosco, Emanuela
author_facet Oehl, Kathrin
Kresoja-Rakic, Jelena
Opitz, Isabelle
Vrugt, Bart
Weder, Walter
Stahel, Rolf
Wild, Peter
Felley-Bosco, Emanuela
author_sort Oehl, Kathrin
collection PubMed
description Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies.
format Online
Article
Text
id pubmed-5829086
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58290862018-03-09 Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression Oehl, Kathrin Kresoja-Rakic, Jelena Opitz, Isabelle Vrugt, Bart Weder, Walter Stahel, Rolf Wild, Peter Felley-Bosco, Emanuela Front Oncol Oncology Experimental models closely representing in vivo conditions allow investigating mechanisms of resistance. Our aims were to establish a live-cell biobank of malignant pleural mesothelioma (MPM) samples and to obtain proof of principle that primary culture chemoresistant models, mimicking tumor progression observed in patients, can be obtained in vitro, providing a useful tool to investigate underlying mechanisms. Primary mesothelioma cultures were established from 235 samples between 2007 and 2014. Of two MPM patients, primary cultures obtained at different time points: at initial diagnosis, after neoadjuvant treatment at surgery and/or after tumor recurrence, were deeply investigated. Cells and corresponding tumor tissue were characterized by mesothelial protein and gene expression analysis. In addition, primary cultures from chemo naive patients were exposed to increasing doses of cisplatin/pemetrexed during three months and compared with non-treated cells in a cytotoxicity assay, and by selected profiling of senescence markers. In vitro chemoresistance in the primary mesothelioma cell cultures was associated with increased Thy1 (CD90) expression. Thy1 expression in MPM samples was significantly associated with poor overall survival in the TCGA MPM cohort. Our results illustrate that the establishment of a large live-cell MPM biobank contributes to a better understanding of therapy resistance observed in vivo, which eventually may lead to a more logical approach for developing new treatment strategies. Frontiers Media S.A. 2018-02-23 /pmc/articles/PMC5829086/ /pubmed/29527515 http://dx.doi.org/10.3389/fonc.2018.00040 Text en Copyright © 2018 Oehl, Kresoja-Rakic, Opitz, Vrugt, Weder, Stahel, Wild and Felley-Bosco. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Oehl, Kathrin
Kresoja-Rakic, Jelena
Opitz, Isabelle
Vrugt, Bart
Weder, Walter
Stahel, Rolf
Wild, Peter
Felley-Bosco, Emanuela
Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_full Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_fullStr Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_full_unstemmed Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_short Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression
title_sort live-cell mesothelioma biobank to explore mechanisms of tumor progression
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829086/
https://www.ncbi.nlm.nih.gov/pubmed/29527515
http://dx.doi.org/10.3389/fonc.2018.00040
work_keys_str_mv AT oehlkathrin livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT kresojarakicjelena livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT opitzisabelle livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT vrugtbart livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT wederwalter livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT stahelrolf livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT wildpeter livecellmesotheliomabiobanktoexploremechanismsoftumorprogression
AT felleyboscoemanuela livecellmesotheliomabiobanktoexploremechanismsoftumorprogression